Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
Top Cited Papers
Open Access
- 31 March 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (7), 1553-1558
- https://doi.org/10.1158/1078-0432.ccr-15-2035
Abstract
Cancer clinical trials have relied on overall survival and measures of tumor growth or reduction to assess the efficacy of a drug. However, benefits are often accompanied by significant symptomatic toxicities. The degree to which a therapy improves disease symptoms and introduces symptomatic toxicity affects how patients function in their daily lives. These concepts are important contributors to health-related quality of life (HRQOL). In this article, we discuss patient-reported outcome (PRO) assessment in cancer trials and challenges relying solely on static multi-item HRQOL instruments. We propose focusing on three separate measures of well-defined concepts: symptomatic adverse events, physical function, and disease-related symptoms, which are key contributors to the effect of a therapy on HRQOL. Separate measures of these three concepts may facilitate the incorporation of emerging contemporary instruments that can tailor the PRO assessment strategy to different trial contexts. Irrespective of the PRO measures used, continued improvement in trial design and conduct is crucial to decrease missing data and optimize the quality of PRO information. International stakeholder collaboration and continued research into optimal practices for PRO and other clinical outcome assessments are necessary to advance a common framework for generating and reporting rigorous patient-centered data from cancer clinical trials. Clin Cancer Res; 22(7); 1553–8. ©2016 AACR.Keywords
This publication has 19 references indexed in Scilit:
- Recommended Patient-Reported Core Set of Symptoms and Quality-of-Life Domains to Measure in Ovarian Cancer Treatment TrialsJNCI Journal of the National Cancer Institute, 2014
- Recommended Patient-Reported Core Set of Symptoms to Measure in Head and Neck Cancer Treatment TrialsJNCI Journal of the National Cancer Institute, 2014
- The PROMIS Physical Function item bank was calibrated to a standardized metric and shown to improve measurement efficiencyJournal of Clinical Epidemiology, 2014
- The impact of functional limitations on long-term outcomes among African-American and white women with breast cancer: a cohort studyBMJ Open, 2013
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk MyelofibrosisClinical Cancer Research, 2012
- Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimensionQuality of Life Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive CachexiaClinical Cancer Research, 2007
- Assessing the Clinical Significance of Single Items Relative to Summated ScoresMayo Clinic Proceedings, 2002
- A validation study of the domains of the core EORTC Quality of Life QuestionnaireQuality of Life Research, 1993